ONLY OPT-E-SCRIP OFFERS A FORMULARY WHICH GIVES EACH EMPLOYEE THE ATTENTION THEY NEED AND THE COST SAVINGS YOU WANT

Traditional drug benefit cost control has focused on formulary designs which seek to generate savings from your entire employee population based on incentives such as tiered co-pays that encourage generic and selected name brand drug usage, mandates such as “prior authorization” and step-therapy that make it difficult for doctors to prescribe name brand drugs. To some degree, these approaches can bias the clinical decision making against the individual patient

In contrast, the Opt-e-scrip Formulary recognizes the scientific fact that each patient responds differently to different drugs or may not even respond at all. Our “clinical trial in a box” allows a physician to make evidence-based choices for each patient, which results in better outcomes. Importantly, since name brand drugs are often no better than inexpensive therapeutic substitutes when the individual patient is asked to compare them in a scientifically valid way, the Opt-e-scrip Formulary also results in high utilization of less costly drugs by your employees.
The Opt-e-scrip Formulary:

Helps physicians decide which drug is really better for each patient:

• Physicians can compare two drugs at a time in a single prescription, branded versus generic, and then “weed out” drugs/dosages, which are less safe or effective.
• The Journal of the American Medical Association has indicated that the type of test we use is the best way for a physician to make a treatment decision.

Helps avoid unwanted side effects.

• Our tests reveal that far more side effects occur with chronic care drugs than is generally recognized.
• The better tolerated a drug is, the more likely the patient is to persist in taking it; this results in better control of the chronic disease and lower costs longer term.

Encourages more direct patient involvement in their own healthcare.

• About 75% of patients report they felt the test kits were helpful to them in improving their standard of care.
• About 80% would use it again, preferring the test kits to the traditional “prescribe now --- change it later” approach.
• About 90% said that if the doctor prescribed the test kit, they would use it.

Creates higher levels of generic utilization in order to save money.

• For the three categories that we place in the Formulary in the first year (Osteoarthritis, GERD, Allergic Rhinitis), typically more than 70% of patients will be identified based on each patient’s own data who would receive equal or better clinical outcomes from an inexpensive therapeutic substitute.
• Since our tests typically result in high double-digit utilization rates of inexpensive drugs, for each additional 1% increase in generic utilization rates over your current rates, you can generally expect a 1% savings.
• The top 12 chronic disease categories alone control over half of all drug costs—meaning the Opt-escrip Formulary could reduce your overall drug costs by 25-30% once all test kits are phased into your drug benefit plan design.